{"title":"应将甲状腺炎列为新冠疫苗不良反应之一","authors":"N. Mikhail","doi":"10.37191/mapsci-jidm-1(1)-005","DOIUrl":null,"url":null,"abstract":"Background: Several cases of thyroiditis were recently reported in individuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19).\n\nObjective: To determine characteristics of thyroiditis occurring following SARS-CoV-2 vaccination.\n\nMethods: PubMed search up to April 26, 2022. Search terms are thyroiditis, SARS-Cov-2, vaccine, COVID-19. Case reports, case series, review articles and pertinent in vitro studies in English, Spanish and French are reviewed.\n\nResults: Review of literature revealed 97 patients with thyroiditis (71.3% women, age range 26-82 year-old) occurring following vaccination against SARS-CoV-2. Subjects reported from Turkey alone contributed to 50.5% of all cases. Seven cases (7.2%) presented with silent (painless) thyroiditis. Onset of thyroiditis symptoms ranged from 12 hours to 12 weeks after vaccination. In 74.2% of patients, these symptoms started between 3 to 15 days post-vaccination. The most frequently implicated vaccine was Pfizer-BioNTech vaccine (55.7% of cases) followed by CoronaVac (21.6%), Moderna (8.5%) and AstraZeneca (6.1%). Thyroiditis cases were equally triggered after the first and second vaccine dose. Personal and family history of thyroid diseases and autoimmune diseases were uncommon (<5%). Among 7 patients who were re-vaccinated, 5 did not have relapse of thyroiditis, whereas 2 subjects had recurrence or worsening of thyroiditis symptoms. Clinical picture and course of thyroiditis induced by the vaccine generally mimic those of non-vaccine-related classic thyroiditis. Mechanisms of thyroiditis after COVID-19 vaccination are unclear but there is evidence of genetic predisposition related to specific human leukocyte antigens (HLA) haplotypes. Glucocorticoid therapy of thyroiditis may virtually decrease COVID-19 vaccine immunogenicity.\n\nConclusion: Thyroiditis should be listed among adverse effects of COVID-19 vaccines to alert physicians and avoid misdiagnosis and unnecessary investigations. If possible, it may be better to avoid its treatment with glucocorticoids.","PeriodicalId":177340,"journal":{"name":"Journal of Infectious Diseases & Microbiology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Thyroiditis Should be Listed Among Adverse Effects of Covid-19 Vaccination\",\"authors\":\"N. Mikhail\",\"doi\":\"10.37191/mapsci-jidm-1(1)-005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Several cases of thyroiditis were recently reported in individuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19).\\n\\nObjective: To determine characteristics of thyroiditis occurring following SARS-CoV-2 vaccination.\\n\\nMethods: PubMed search up to April 26, 2022. Search terms are thyroiditis, SARS-Cov-2, vaccine, COVID-19. Case reports, case series, review articles and pertinent in vitro studies in English, Spanish and French are reviewed.\\n\\nResults: Review of literature revealed 97 patients with thyroiditis (71.3% women, age range 26-82 year-old) occurring following vaccination against SARS-CoV-2. Subjects reported from Turkey alone contributed to 50.5% of all cases. Seven cases (7.2%) presented with silent (painless) thyroiditis. Onset of thyroiditis symptoms ranged from 12 hours to 12 weeks after vaccination. In 74.2% of patients, these symptoms started between 3 to 15 days post-vaccination. The most frequently implicated vaccine was Pfizer-BioNTech vaccine (55.7% of cases) followed by CoronaVac (21.6%), Moderna (8.5%) and AstraZeneca (6.1%). Thyroiditis cases were equally triggered after the first and second vaccine dose. Personal and family history of thyroid diseases and autoimmune diseases were uncommon (<5%). Among 7 patients who were re-vaccinated, 5 did not have relapse of thyroiditis, whereas 2 subjects had recurrence or worsening of thyroiditis symptoms. Clinical picture and course of thyroiditis induced by the vaccine generally mimic those of non-vaccine-related classic thyroiditis. Mechanisms of thyroiditis after COVID-19 vaccination are unclear but there is evidence of genetic predisposition related to specific human leukocyte antigens (HLA) haplotypes. Glucocorticoid therapy of thyroiditis may virtually decrease COVID-19 vaccine immunogenicity.\\n\\nConclusion: Thyroiditis should be listed among adverse effects of COVID-19 vaccines to alert physicians and avoid misdiagnosis and unnecessary investigations. If possible, it may be better to avoid its treatment with glucocorticoids.\",\"PeriodicalId\":177340,\"journal\":{\"name\":\"Journal of Infectious Diseases & Microbiology\",\"volume\":\"25 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infectious Diseases & Microbiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37191/mapsci-jidm-1(1)-005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectious Diseases & Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37191/mapsci-jidm-1(1)-005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Thyroiditis Should be Listed Among Adverse Effects of Covid-19 Vaccination
Background: Several cases of thyroiditis were recently reported in individuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19).
Objective: To determine characteristics of thyroiditis occurring following SARS-CoV-2 vaccination.
Methods: PubMed search up to April 26, 2022. Search terms are thyroiditis, SARS-Cov-2, vaccine, COVID-19. Case reports, case series, review articles and pertinent in vitro studies in English, Spanish and French are reviewed.
Results: Review of literature revealed 97 patients with thyroiditis (71.3% women, age range 26-82 year-old) occurring following vaccination against SARS-CoV-2. Subjects reported from Turkey alone contributed to 50.5% of all cases. Seven cases (7.2%) presented with silent (painless) thyroiditis. Onset of thyroiditis symptoms ranged from 12 hours to 12 weeks after vaccination. In 74.2% of patients, these symptoms started between 3 to 15 days post-vaccination. The most frequently implicated vaccine was Pfizer-BioNTech vaccine (55.7% of cases) followed by CoronaVac (21.6%), Moderna (8.5%) and AstraZeneca (6.1%). Thyroiditis cases were equally triggered after the first and second vaccine dose. Personal and family history of thyroid diseases and autoimmune diseases were uncommon (<5%). Among 7 patients who were re-vaccinated, 5 did not have relapse of thyroiditis, whereas 2 subjects had recurrence or worsening of thyroiditis symptoms. Clinical picture and course of thyroiditis induced by the vaccine generally mimic those of non-vaccine-related classic thyroiditis. Mechanisms of thyroiditis after COVID-19 vaccination are unclear but there is evidence of genetic predisposition related to specific human leukocyte antigens (HLA) haplotypes. Glucocorticoid therapy of thyroiditis may virtually decrease COVID-19 vaccine immunogenicity.
Conclusion: Thyroiditis should be listed among adverse effects of COVID-19 vaccines to alert physicians and avoid misdiagnosis and unnecessary investigations. If possible, it may be better to avoid its treatment with glucocorticoids.